TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29080924

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 728

Group type: COMPARATOR
Intervention: Control (treatment without panitumumab)
Number of subjects: 728
Study: 26731113

Group type: EXPERIMENTAL
Intervention: Promitor™ Soluble Corn Fibre (SCF) at 6 g/fibre/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Promitor™ Soluble Corn Fibre (SCF) at 12 g/fibre/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Promitor™ Soluble Corn Fibre (SCF) at 18 g/fibre/day
Number of subjects: 24
Study: 24117908

Group type: EXPERIMENTAL
Intervention: Protocol-defined pharmacist care (intervention group)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Usual pharmacist care (control group)
Number of subjects: 734
Study: 22004115

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 2
Study: 18679401

Group type: EXPERIMENTAL
Intervention: Transanal irrigation using Peristeen Anal Irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative bowel management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 0
Study: 17374331

Group type: EXPERIMENTAL
Intervention: Methotrexate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: PUVA therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of PUVA to methotrexate
Number of subjects: 0
Study: 15650986

Group type: EXPERIMENTAL
Intervention: Morphine HCl (1 mg/mL) with an infusion rate of 0.3 mg/h and 1‐mg bolus doses
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fentanyl (50 microg/mL) with an infusion rate of 1 microg/kg/h and 10‐microg bolus
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil (50 microg/mL) with an infusion rate of 0.05 microg/kg/min and 0.5‐microg/kg bolus
Number of subjects: 75
Study: 11173324

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 25

Group type: COMPARATOR
Intervention: H pylori-positive DU patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cure of H pylori
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 25
Study: 10968183

Group type: COMPARATOR
Intervention: Closed reduction and splint immobilization
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 28
Study: 8150634

Group type: EXPERIMENTAL
Intervention: Retrograde venous perfusion (RVP) with netilmycin, once/day for 10 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Systemic venous infusions (SVI) with netilmycin, three times/day for 10 days
Number of subjects: 45
Study: 3254824

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin + Cholestyramine
Number of subjects: 40
Study: 29373242

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) cream 0.05%
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 54
Study: 27197727

Group type: EXPERIMENTAL
Intervention: Transmeatal low‐level laser therapy for tinnitus
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Worry assessment
Number of subjects: 54
Study: 24479529

Group type: EXPERIMENTAL
Intervention: Male avatar in competitive setting against two female avatars
Number of subjects: 120

Group type: COMPARATOR
Intervention: Female avatar in competitive setting against two male avatars
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Male avatar in cooperative setting
Number of subjects: 120

Group type: COMPARATOR
Intervention: Female avatar in cooperative setting
Number of subjects: 120
Study: 22641777

Group type: EXPERIMENTAL
Intervention: Exercise training for 3 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (10 healthy sedentary individuals)
Number of subjects: 19
Study: 20176167

Group type: EXPERIMENTAL
Intervention: Intramedullary fixation (Gamma nail, Stryker Howmedica; Endovis BA, Citieffe)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dynamic hip screw and plate (DHS, Synthes‐Stratec)
Number of subjects: 120
Study: 18312937

Group type: EXPERIMENTAL
Intervention: Intracavernosal saline infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 33
Study: 16151336

Group type: EXPERIMENTAL
Intervention: Etanercept (ETA) 25 mg SC twice weekly for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 20
Study: 12063369

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2010
Study: 10490438

Group type: EXPERIMENTAL
Intervention: 3.75 mg triptorelin intramuscularly every four weeks (group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 46
Study: 8628471

Group type: EXPERIMENTAL
Intervention: Coagulant or antiaggregant therapy, surgical closure of PFO
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Interatrial communication, recent migraine history, posterior cerebral artery territory infarct, coexisting cause of stroke
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Interatrial septum aneurysm (ISA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Treatment type (coagulant or antiaggregant therapy, surgical closure of PFO)
Number of subjects: 140
Study: 8351156

Group type: EXPERIMENTAL
Intervention: Tizanidine (TZD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 3524513

Group type: EXPERIMENTAL
Intervention: Clinic treatment by a speech pathologist for 12 weeks, followed by 12 weeks of no treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home treatment by a trained volunteer for 12 weeks, followed by 12 weeks of no treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred treatment for 12 weeks, followed by 12 weeks of treatment by a speech pathologist
Number of subjects: 0
Study: 29973664

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM) performed during even months (cord milked three times)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no UCM) during odd months
Number of subjects: 101
Study: 26924488

Group type: EXPERIMENTAL
Intervention: SASA! community mobilisation intervention
Number of subjects: 351
Study: 25454938

Group type: EXPERIMENTAL
Intervention: Automated adjustment of FiO2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Manual adjustment of FiO2
Number of subjects: 15
Study: 23548995

Group type: EXPERIMENTAL
Intervention: Counseling intervention focused on promoting totally smoke‐free homes and cars (TSFHC) with self‐help booklet and three gifts; 110 women received this intervention.
Number of subjects: 218

Group type: COMPARATOR
Intervention: Self‐help booklet promoting TSFHC; all participants received this.
Number of subjects: 218
Study: 22099904

Group type: EXPERIMENTAL
Intervention: EndoVac (EV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rispi-Sonic/MicroMega 1500 (MM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Syringe irrigation with a slot-tipped needle (SN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EndoActivator (EA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 19508159

Group type: EXPERIMENTAL
Intervention: High-dose (HD) trivalent, inactivated influenza vaccine (60 microg of hemagglutinin per strain)
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Standard-dose (SD) trivalent, inactivated influenza vaccine (15 microg of hemagglutinin per strain)
Number of subjects: 3837

Group type: EXPERIMENTAL
Intervention: High-dose (HD) trivalent, inactivated influenza vaccine
Number of subjects: 3837
Study: 16817038

Group type: EXPERIMENTAL
Intervention: ACKD present in 48 (55.8%) patients; 24 (50%) had grade 1 ACKD and 24 (50%) had grade 2 ACKD.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: AH detected before HD in 68 (79.1%) patients and after HD in 54 (62.8%) patients.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Duration of dialysis treatment.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diameter of the inferior vena cava measured three hours after HD.
Number of subjects: 86
Study: 12614804

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia (IAWBC) at 33 degrees C
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intermittent antegrade cold blood cardioplegia at 4 degrees C
Number of subjects: 200
Study: 10688090

Group type: EXPERIMENTAL
Intervention: SS-cream 0.20 g
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo 0.20 g
Number of subjects: 106
Study: 7593873

Group type: EXPERIMENTAL
Intervention: Demandingness during interactions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Withdrawal during interactions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Withdrawal by men and woman demand-man withdraw during discussions identified by women
Number of subjects: 48
Study: 1903404

Group type: COMPARATOR
Intervention: recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 108
Study: 7045440

Group type: EXPERIMENTAL
Intervention: Cephalexin (10-day courses, repeated whenever susceptible bacteriuria was present)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no antibiotic treatment)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 35
Study: 30244979

Group type: EXPERIMENTAL
Intervention: Ankle joint mobilization
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Triceps surae stretching
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 28253033

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 517
Study: 26419293

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1037
Study: 24047339

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (62-70 Gy in 31-35 fractions)
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Conventional radiotherapy (62-70 Gy in 31-35 fractions)
Number of subjects: 1476
Study: 21332937

Group type: EXPERIMENTAL
Intervention: Four-times faster infusion rate delivery (FIRD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slower infusion rate delivery (SIRD)
Number of subjects: 0
Study: 19919768

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for asymptomatic children aged <6 years
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Screening for tuberculosis (TB) disease
Number of subjects: 220
Study: 16913429

Group type: EXPERIMENTAL
Intervention: Unexpected impact (4.5 m/s2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Unexpected impact (10.1 m/s2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Expected impact (10.1 m/s2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Impact awareness (all impacts)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Timing of masticatory muscle response
Number of subjects: 29
Study: 15497711

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32
Study: 11379842

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy
Number of subjects: 113
Study: 9416380

Group type: EXPERIMENTAL
Intervention: Modified heparin dosing nomogram (institution-specific)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician-directed dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmodified heparin dosing nomogram (18 units/kg/h)
Number of subjects: 0
Study: 8311278

Group type: EXPERIMENTAL
Intervention: S (+) ketamine (1 mg/kg, Group I, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Racemic ketamine (2 mg/kg, Group II, n = 30)
Number of subjects: 60
Study: 3276360

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 179

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 179
Study: 31286658

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 16
Study: 28453453

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) for 25 minutes per session, two sessions per week for 4 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Magnetic therapy for 50 minutes per session, two sessions per week for 4 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Pharmacological treatment alone (control group)
Number of subjects: 85
Study: 26775369

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 90
Study: 23182407

Group type: EXPERIMENTAL
Intervention: 0.5 mg pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21196428

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for 30 minutes before and throughout heel stick
Number of subjects: 28
Study: 18458518

Group type: EXPERIMENTAL
Intervention: Integrated symptom management program for 6 months (tailored education, stress management, exercise, diet, deep breathing, music therapy, periodical telephone monitoring, daily log)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Integrated symptom management program for 6 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 16569351

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (15 mg aerosolized, twice daily for 10 days)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanate (50 mg/Kg, twice daily for 10 days)
Number of subjects: 311
Study: 12660683

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (all doses)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 10913038

Group type: EXPERIMENTAL
Intervention: Endurance training (T)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary (S)
Number of subjects: 16
Study: 9014623

Group type: EXPERIMENTAL
Intervention: Methohexitone (group M)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 42
Study: 1395889

Group type: EXPERIMENTAL
Intervention: Intravenous injection of aminophylline slowly
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional three drugs combination treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between group A and B
Number of subjects: 80
Study: 3887851

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29567846

Group type: EXPERIMENTAL
Intervention: Midwife-led continuity model (intervention clinics)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 39
Study: 26740634

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 12
Study: 24905629

Group type: EXPERIMENTAL
Intervention: Ephedrine/caffeine combination (200/20 mg, n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 13
Study: 22301417

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) twice daily after a 14-day once-daily lead-in period
Number of subjects: 359
Study: 19952998

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 125
Study: 17106838

Group type: EXPERIMENTAL
Intervention: Day hospital detoxification treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study: 15704504

Group type: EXPERIMENTAL
Intervention: Inhibition tape
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Facilitation tape
Number of subjects: 30

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 30
Study: 12218740

Group type: EXPERIMENTAL
Intervention: Long bout (one 30-min walk per day, 5 days/week)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Short bouts (three 10-min walks per day, 5 days/week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 21
Study: 10086941

Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg or one puff twice daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 49
Study: 7885808

Group type: EXPERIMENTAL
Intervention: Stimulus distribution including water in the stimulus set (Experiments 1-3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of subjective ranges of two taste qualities (Experiment 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of expected response distribution (Experiments 5-6)
Number of subjects: 0
Study: 2236711

Group type: EXPERIMENTAL
Intervention: 3.5 mg bupivacaine 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 7 ml bupivacaine 0.25%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.175%
Number of subjects: 60
Study: 1266755

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 150
Study: 31355770

Group type: EXPERIMENTAL
Intervention: Hand scaling followed by glycine powder air polishing (GPAP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling followed by glycine powder air polishing (GPAP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hand scaling alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 50
Study: 28795506

Group type: EXPERIMENTAL
Intervention: D-4F 300 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: D-4F 500 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25441237

Group type: EXPERIMENTAL
Intervention: Self-directed multicomponent exercise program
Number of subjects: 401

Group type: COMPARATOR
Intervention: Nutrition control program
Number of subjects: 401
Study: 24315327

Group type: EXPERIMENTAL
Intervention: Value of Information (VoI) analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision analysis (DA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further research
Number of subjects: 0
Study: 21378155

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19382472

Group type: EXPERIMENTAL
Intervention: Hydrotherapy with Chinese drugs (HT‐C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional functional training
Number of subjects: 100
Study: 17365264

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (either dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15479320

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (Xe, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA, n = 19)
Number of subjects: 39
Study: 11583193

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 on days 1 + 8 of a three-week schedule combined with carboplatin AUC 4 on day 1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Carboplatin alone (control group in a future randomized trial)
Number of subjects: 26
Study: 9676348

Group type: EXPERIMENTAL
Intervention: Batch at the lower in vitro specification range
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Batch at the upper in vitro specification range
Number of subjects: 18

Group type: COMPARATOR
Intervention: Batch in the middle of the in vitro specification range
Number of subjects: 18
Study: 7933396

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 20
Study: 2894780

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Trihexyphenidyl
Number of subjects: 9
Study: 30486656

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention combining cognitive stimulation group and tai chi (14 sessions, twice a week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treat as usual
Number of subjects: 80
Study: 29453687

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Boosted ARTs
Number of subjects: 44
Study: 27167637

Group type: EXPERIMENTAL
Intervention: Early palliative care (PC) integrated with standard oncology care (SC)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Early palliative care (PC)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard oncology care (SC)
Number of subjects: 151
Study: 24625936

Group type: EXPERIMENTAL
Intervention: Atropine plus pralidoxime
Number of subjects: 120

Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 120
Study: 23375824

Group type: EXPERIMENTAL
Intervention: Four-unit media education program including one unit on gambling, implemented by trained teachers during class time.
Number of subjects: 2109

Group type: COMPARATOR
Intervention: Regular classes without any specific intervention (control group).
Number of subjects: 2109
Study: 20636656

Group type: EXPERIMENTAL
Intervention: Intervention group (social network trial)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Control group (matched case-control study)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Post-incarceration behaviors
Number of subjects: 950
Study: 18268065

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) + L-arginine (ARG)
Number of subjects: 24
Study: 15901520

Group type: EXPERIMENTAL
Intervention: Condom failure
Number of subjects: 921